FRANCISCO DE PAULA
TELLEZ PEREZ
Profesor asociado de Ciencias de la Salud
Instituto de Biomedicina de Sevilla
Sevilla, EspañaPublikationen in Zusammenarbeit mit Forschern von Instituto de Biomedicina de Sevilla (17)
2023
-
Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice
Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 10, pp. 2591-2596
2022
-
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
Journal of Infection, Vol. 85, Núm. 3, pp. 322-326
2019
-
Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 361-366
2018
-
Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort
Journal of Viral Hepatitis, Vol. 25, Núm. 6, pp. 699-706
2017
-
Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients
HIV Medicine, Vol. 18, Núm. 8, pp. 546-554
-
HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study
HIV Clinical Trials, Vol. 18, Núm. 3, pp. 126-134
-
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8
2016
-
Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: The HEPAVIR SEG-HEP Cohort
PLoS ONE, Vol. 11, Núm. 2
-
No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: A multicentric retrospective study from 2000-2014
BMC Infectious Diseases, Vol. 16, Núm. 1
-
The PNPLA3 genetic variant rs738409 influences the progression to cirrhosis in HIV/ Hepatitis C virus coinfected patients
PLoS ONE, Vol. 11, Núm. 12
2015
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
-
Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C
Journal of Infection, Vol. 71, Núm. 5, pp. 571-577
-
Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals
AIDS, Vol. 29, Núm. 15, pp. 1927-1935
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
-
Risk of liver decompensation among HIV/Hepatitis C virus-coinfected individuals with advanced fibrosis: Implications for the timing of therapy
Clinical Infectious Diseases, Vol. 57, Núm. 10, pp. 1401-1408
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
2012
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726